{
  "source": "PA-Med-Nec-Wakix.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2174-8\nProgram Prior Authorization/Medical Necessity\nMedication Wakix® (pitolisant)\nP&T Approval Date 10/2019, 12/2019, 4/2020, 3/2021, 6/2021, 6/2022, 10/2023, 9/2024\nEffective Date 12/1/2024\n1. Background:\nWakix is a histamine-3 (H3) receptor antagonist/inverse agonist indicated for the treatment of\nexcessive daytime sleepiness (EDS) or cataplexy in adult and pediatric patients 6 years of age and\nolder with narcolepsy.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\n© 2024 UnitedHealthcare Services, Inc.\n1\nA. Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)\n1. Initial Authorization\na. Wakix will be approved based on all of the following criteria:\n(1) Submission of medical records (e.g. chart notes, lab values) documenting a diagnosis of\nnarcolepsy with both of the following:\n(a) The patient has daily periods of irrepressible need to sleep or daytime lapses into\nsleep occurring for at least three months.\n(b) A mean sleep latency of ≤ 8 minutes and two or more sleep onset REM periods\n(SOREMPs) are found on a MSLT performed according to standard techniques\nfollowing a normal overnight polysomnogram. A SOREMP (within 15 minutes of\nsleep onset) on the preceding nocturnal polysomnogram may replace one of the\nSOREMPs on the MSLT.\n-AND-\n(2) Physician attestation to the following:\n(a) Other causes of sleepiness have been ruled out or treated (including but not limited to\nobstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of\nsubstances or medications or their withdrawal, sleep phase disorder, or other sleep\ndisorders).\n-AND-\n(3) One of the following:\n(a) History of failure, contraindication, or intolerance to all of the following:\n(i) armodafinil (Nuvigil) or modafinil (Provigil)\n(ii) an amphetamine (e.g., amphetamine, dextroamphetamine) or methylphenidate\nbased stimulant\n(iii) Sunosi\n-OR-\n(b) History of or potential for a substanc",
    "armodafinil (Nuvigil) or modafinil (Provigil)\n(ii) an amphetamine (e.g., amphetamine, dextroamphetamine) or methylphenidate\nbased stimulant\n(iii) Sunosi\n-OR-\n(b) History of or potential for a substance abuse disorder\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Neurologist\n(b) Psychiatrist\n(c) Pulmonologist\n© 2024 UnitedHealthcare Services, Inc.\n2\n(d) Sleep Medicine Specialist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Wakix will be approved for continuation of therapy based on the following criterion:\n(1) Reduction in symptoms of excessive daytime sleepiness associated with Wakix therapy\nAuthorization will be issued for 12 months.\nB. Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)\n1. Initial Authorization\na. Wakix will be approved based on all of the following criteria:\n(1) Submission of medical records (e.g. chart notes, lab values) documenting a diagnosis of\nnarcolepsy with cataplexy (i.e., Narcolepsy Type 1) with both of the following:\n(a) The patient has daily periods of irrepressible need to sleep or daytime lapses into\nsleep occurring for at least three months.\n(b) A mean sleep latency of ≤ 8 minutes and two or more sleep onset REM periods\n(SOREMPs) are found on a MSLT performed according to standard techniques\nfollowing a normal overnight polysomnogram. A SOREMP (within 15 minutes of\nsleep onset) on the preceding nocturnal polysomnogram may replace one of the\nSOREMPs on the MSLT.\n-AND-\n(2) Physician attestation to both of the following:\n(a) Patient has experienced cataplexy defined as more than one episode of sudden loss of\nmuscle tone with retained consciousness\n-AND-\n(b) Other causes of sleepiness have been ruled out or treated (including but not limited to\nobstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of\nsubstances or medications or their withdrawal, sleep phase disorder, or other sleep\ndisorders).\n-AND-\n(3) Prescribed by or in consultation with one of the following:\n©",
    "rome, shift work, the effects of\nsubstances or medications or their withdrawal, sleep phase disorder, or other sleep\ndisorders).\n-AND-\n(3) Prescribed by or in consultation with one of the following:\n© 2024 UnitedHealthcare Services, Inc.\n3\n(a) Neurologist\n(b) Psychiatrist\n(c) Pulmonologist\n(d) Sleep Medicine Specialist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Wakix will be approved for continuation of therapy based on one of the following criteria:\n(1) Reduction in frequency of cataplexy attacks associated with therapy\n–OR–\n(2) Reduction in symptoms of excessive daytime sleepiness associated with therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit plan\ncoverage may also impact coverage criteria. Other policies and utilization management programs may\napply\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Wakix [package insert]. Plymouth Meeting, PA: Harmony Biosciences, LLC; June 2024.\n2. American Academy of Sleep Medicine. International Classification of Sleep Disorders:\nDiagnostic and Coding Manual. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.\n3. Sunosi [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; October 2021.\n4. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: An\nAmerican Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep\nMedicine. 2021. Sept (17):1881-1893.\n5. Wise MS1, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of\ncentral origin. Sleep. 2007 Dec;30(12):1712-27.\nProgram Prior Authorization/Medical Ne",
    "1. Sept (17):1881-1893.\n5. Wise MS1, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of\ncentral origin. Sleep. 2007 Dec;30(12):1712-27.\nProgram Prior Authorization/Medical Necessity - Wakix® (pitolisant)\nChange Control\n11/2019 New program\n12/2019 Added requirement for history of Sunosi.\n4/2020 Added requirement for submission of documentation of sleep study\nwith specific sleep study requirements. Added requirement for\n© 2024 UnitedHealthcare Services, Inc.\n4\nprescriber specialty. Changed initial authorization duration to 12\nmonths.\n3/2021 Added criteria for narcolepsy with cataplexy based on updated product\nlabeling.\n6/2021 Updated Type 1 narcolepsy section to clarify that medical records\nsubmitted show narcolepsy with cataplexy and provider attestation for\ncataplexy symptoms. Added pulmonologist to the list of specialists.\n6/2022 Annual review. Updated references.\n10/2023 Annual review. Updated references.\n9/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}